Unique among 5-ASAs, only PENTASA® has ethyl cellulose coated microgranules.3-18
These consistently release mesalazine throughout the whole colon at all enteral pH conditions, independent of food co-administration.3-6
Prescribe PENTASA® for your paediatric* patients because:
PENTASA® demonstrated complete remission† in mild to moderate paediatric* UC patients at week 61
The formulations include 1g, 2g and 4g sachets, which may reduce pill burden and encourage patient adherence2, 4-6
89% of paediatric* patients were found to be compliant to therapy at week 6 of a randomised controlled trial1
PENTASA® can be taken independent of food or in yoghurt at any time of the day to fit in with your paediatric* patients’ daily routine, making them more convenient than ever4-6
*PENTASA® (500mg tablets, 1g, 2g and 4g sachets) is licensed in children 6 years of age and older, and given in divided doses. †Complete remission was defined as remission (PUCAI<10 points) and a change of at least 10 points from baseline.
Turner D, et al. J Crohn’s Colitis. 2017;11:527–533.
Ye B and van Langenberg DR. World J Gastrointest PharmacolTher.2015;6(4):137-144.
Job Code: UK-PA-2000023 - Date of preparation: October 2020
Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.